


Cite this: *RSC Adv.*, 2020, 10, 22966

Inhibitory effects of UDP-glucuronosyltransferase (UGT) typical ligands against *E. coli* beta-glucuronidase (GUS)

Ling Xiao,^a Dehui Chi,^b Guiju Sheng,^b Wenjuan Li,^b Penghui Lin,^c Sicheng Liang,^d Liangliang Zhu^{id}*^b and Peipei Dong^{*e}

UDP-glucuronosyltransferases (UGTs) and β -glucuronidase (GUS) catalyze entirely distinct metabolism reactions. UGTs are responsible for the glucuronidation of a variety of drugs, endogenous and environmental chemicals, whereas GUS hydrolyzes glucuronides and liberates the parent substrates. Information on the overlap of ligand selectivity between UGT and GUS is essential for exploring the pharmacological or toxicological effects of the inhibitors of these two metabolic enzymes. This study is conducted to test whether UGTs and GUS share common ligands, by investigating the inhibitory effects towards *E. coli* GUS by a series of UGT typical substrates and inhibitors. Results showed that three typical ligands of UGTs, including two specific substrates (estradiol and trifluoperazine, E2 and TFP) and one selective inhibitor (magnolol, Mag), can inhibit the activity of GUS. Kinetic assays indicated that all the three UGT specific chemicals displayed competitive inhibition, with K_i values of 31.4 (E2), 56.9 (TFP), and 16.6 μ M (Mag). Docking studies further revealed that the three chemicals can enter the active sites of GUS by forming contacts with residues Glu-413, Trp-549, Asp-163, Tyr-472, Arg-562, or bound water. Our study indicates that ligand selectivity overlaps between UGTs and GUS, and some chemicals can act as co-inhibitors of these two metabolic enzymes. The pharmacological or toxicological effects of those co-inhibitors require further investigations.

Received 12th March 2020
Accepted 30th May 2020

DOI: 10.1039/d0ra02311f

rsc.li/rsc-advances

Introduction

UDP-glucuronosyltransferases (UGTs) and β -glucuronidase (GUS) catalyse entirely distinct reactions. UGTs are responsible for the conjugation of a variety of clinical drugs, endogenous hormones, food chemicals and environmental toxicants with the glucuronic acid moiety.¹ After undergoing the glucuronidation metabolism, the parent chemicals are commonly inactivated and become more water soluble and are readily excreted.² In contrast to UGTs, GUS catalyses the hydrolysis of glucuronides, liberating the parent endo- and xeno-biotics.³ As

a result, the parent chemicals continue to exert their biological activities or even toxicities.⁴

It is currently believed that the impaired glucuronidation activities can cause undesired effects resulting from the slow elimination of toxic chemicals (e.g. bilirubin and SN-38).^{5,6} To date, a massive number of chemicals have been reported to be potent *in vitro* inhibitors of UGT enzymes.^{7–9} However, only a limited number of these inhibitors are reported to result in pharmacokinetic drug–drug interactions *via in vivo* inhibition of UGTs.¹⁰ The mechanism for such *in vitro*–*in vivo* discrepancy was mainly attributed to those UGT substrates that are usually glucuronidated by different UGTs.¹⁰ However, the inconsistency may result from other aspects. One possible mechanism is that some UGT inhibitors may simultaneously inhibit the activity of β -glucuronidase (GUS). As a result, the decreased exposures from the glucuronidation metabolism are partly compensated.¹¹ In the presence of one UGT inhibitor, glucuronide formation will be inhibited and the parent substrates will remain in relatively high levels.^{3,4} However, if the UGT inhibitor simultaneously inhibits GUS activity, glucuronide hydrolysis will also be decreased and there will be little replenishment for the parent substrates.¹¹ Thus, the glucuronides will remain in similar levels regardless of the presence of the co-inhibitor.

^aSchool of Resources and Environment, Key Laboratory of Aqueous Environment Protection and Pollution Control of Yangtze River, Anqing Normal University, Anqing 246133, China

^bDepartment of Food Science and Technology, School of Life Science and Research Center of Aquatic Organism Conservation and Water Ecosystem Restoration, Anqing Normal University, No. 1314, North Jixian Road, Anqing 246133, China. E-mail: zhuliangliang@aqnu.edu.cn

^cCenter for Environmental and Systems Biochemistry, Markey Cancer Center, and Dept. of Toxicology & Cancer Biology, University of Kentucky, 789 S. Limestone St, Lexington, KY 40536, USA

^dSchool of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

^eCollege of Integrative Medicine, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian 116044, China. E-mail: dongpeipei11@163.com



Since the reactions catalysed by UGTs and GUS are opposite to each other, it is generally thought that UGTs and GUS are unlikely to share common ligands. UGTs tend to bind lipophilic chemicals, while GUS binds relatively hydrophilic glucuronides.^{3,14} However, it was found that several lipophilic flavonoids (*e.g.* baicalein, quercetin and scutellarin) displayed potent inhibitory effects against GUS from *E. coli*.¹⁵ Interestingly, structures in these inhibitors do not contain the glucuronic acid moiety. These findings encouraged us to conduct this study to test whether the typical ligands of UGT, including specific substrates and selective inhibitors, can inhibit the activity of GUS. It is hoped that this study may provide evidences for ligand selectivity overlaps between UGTs and GUS.

Screening of inhibitory effects


UGT typical ligands	Remaining activity (% of the control)
UDP-glucuronic acid	88
Estradiol (E2)	38
Nifedipine	105
Trifluoperazine (TFP)	45
Hecogenin	72
Entaceponone	98
Magnolol (Mg)	28
Niflumic acid	82
Zidovudine	88
Fluconazole	105
Testosterone	90

[illegible]

activities at 37%, 43% and 26% of the control, respectively. For the other chemicals tested in this study, no significant inhibition was observed, where the remaining activities were at least higher than 70% of the control.

The structure of E2 is shown in Fig. 2A. Kinetic analysis indicated that E2 displayed competitive inhibition towards GUS mediated pNPG hydrolysis (Fig. 2B), with the K_i value determined to be $31.4 \pm 2.0 \mu\text{M}$. Docking studies further revealed that an H-bonding interaction existed between the E2-17-OH and carboxylate of Glu-413 in the active site. Two additional hydrogen bonds were also formed between the H_2O in the crystal structure and E2.

The structure of TFP is displayed in Fig. 3A. As shown in Fig. 3B, the inhibition of GUS by TFP follows the competitive model for the de-glucuronidation of pNPG (Fig. 3B). The K_i value was calculated to be $56.9 \pm 2.1 \mu\text{M}$. Docking analysis indicated that the fluorine atoms seem to be important for the inhibitor-



RSC Adv., 2020, 10, 22966–22971 | 22967




Fig. 4 Molecular structure of Mag (A), Lineweaver–Burk plots for the inhibition of Mag on GUS (B), and the best ranked pose of Mag in the active-site cavity of *E. coli* GUS generated with docking (C).

protein interaction. The fluorine atoms formed an H-bonding interaction with the NH of Trp-549 and three extra H-bonds were formed with H₂O.

Inhibition of GUS by Mag

The structure of Mag is displayed in Fig. 4A. Fig. 4B indicated that Mag inhibited GUS competitively in catalysing the hydrolysis of pNPG, with the K_i value calculated to be $16.6 \pm 0.6 \mu\text{M}$. Docking results (Fig. 4C) indicated that four hydrogen bonds were formed with the residues Asp-163, Tyr-472 and Arg-562. π – π stacking interaction was additionally formed between the benzene rings of Mag and Tyr-472.

Discussion

After testing the inhibitory effects of a series of UGT probe ligands against GUS activity, it was clearly demonstrated that the ligand selectivity overlaps between UGTs and GUS. It is possible that some clinical drugs, environmental chemicals, and endogenous molecules may interfere in the glucuronidation pathway by hindering the hydrolysis of glucuronides. Among the chemicals tested in this study, nilotinib, hecogenin, Mag, niflumic acid and fluconazole were reported to be potent *in vitro* UGT inhibitors.^{16–20} *In vitro*–*in vivo* extrapolation suggested that nilotinib, Mag and fluconazole had potential to induce *in vivo* inhibition of UGTs.^{18–20} *In vivo* inhibition of UGTs has been confirmed for nilotinib and fluconazole.^{21,22} It is consistent with the current study that these two UGT inhibitors lack inhibition towards GUS (Fig. 1). For Mag, although one previous study demonstrated that it can potently inhibit the activity of UGT1A9,¹⁸ this study indicates that *in vivo* UGT inhibition will be neutralized due to the co-inhibition of GUS.

E2, TFP and Mag were reported to be probe ligands for UGT1A1, 1A4 and 1A9, respectively.^{18,23} However, the results did not indicate that the overlapping selectivity with GUS is limited to these three isoforms. Actually, E2 undergoes glucuronidation at both 3-OH and 17-OH sites.²⁴ Although E2-3-*O*-glucuronidation is commonly used as a probe reaction for UGT1A1 in human liver,²³ it is additionally catalysed by other isoforms

including UGT1A3, 1A8, 1A10, 2A1, and 2A2.²⁴ For E2-17-*O*-glucuronidation, multiple UGTs including UGT1A3, 1A4, 1A8, 1A10, 2A1, 2A2, 2B7, and 2B17 are involved.^{24,25} Mag has been identified as a selective inhibitor of UGT1A9 in certain concentration ranges, whereas it also serves as a good substrate to several other different UGTs, in particular for UGT1A10 and 2B7.^{18,26} For TFP, available evidences indicated that it acts as a specific substrate for UGT1A4.²³ However, there is still a lack of information about the inhibition selectivity for other UGTs. Therefore, ligand selectivity overlaps with GUS may occur for each individual UGT isoform.

In this study, all three compounds could be well docked into the active site cavity in a similar way to that adopted by the original ligand in crystallographic complexes. For E2, two H-bonding interactions were found between the 17-OH of E2 and the carboxylate of Glu-413 in the active sites. Besides, there is an additional hydrogen bond between the 3-OH of E2 and a H₂O molecule in the crystal structure (Fig. 2C). As shown in Fig. 3C, the fluorine atoms are important for the inhibitor–protein interaction for TFP. F atoms formed an H-bonding interaction with the NH of Trp-549, as well as other three H-bonds with H₂O molecules. For Mag, two phenolic hydroxyl groups are important for the inhibition activity. They formed four H-bonds with the residues Asp-163, Tyr-472 and Arg-562. In addition, π – π stacking interaction was formed between the benzene rings of Mag and Tyr-472. The smaller molecular volume was another merit for Mag to enter the active site cavity (Fig. 4C). From the above analysis, we can see that the polar functional groups including the hydroxyl, phenolic hydroxyl and fluoroalkane appear to be essential for the GUS inhibition.

In the active sites of GUS (*E. coli*), Glu-413 and Glu-504 are important catalytic residues for substrate recognition and hydrolysis.¹² It was found that the competitive inhibitor D-saccharic acid 1,4-lactone can form contacts with Glu-413, Glu-504, Asp-163, Arg-562, Lys-568, Tyr-472, and His-330.¹² Trp-549 was also proved important in binding a cyclic thioimidazole derivative.¹² Rasmussen *et al.* (2011) demonstrated that the bound water could also interact with the potent competitive inhibitor uronic-noeurostegine.²⁷ This study indicated that E2 and TFP could also interact with the bound water. Interactions with the catalytic residues and other important amino acids constituting the active site made these three ligands inhibitors of GUS. Without structural information, it is currently hard to describe the interaction pattern between UGTs and its probe ligands.

It is well known that the inhibition of GUS could help protect humans from irinotecan related digestive tract toxicity by blocking the hydrolysis of SN-38 glucuronides.⁴ E2 serves as an important endogenous chemical in humans, which is also widely used in hormone replacement treatment in clinics.²⁸ It is found that the daily total fecal excretion of E2 can reach 393 μg .²⁹ Given that the minimal colon cavity volume was reported to be only 180 mL,³⁰ the normal physiological E2 concentration in the gut may reach approximately 7.8 μM , which is one quarter of the K_i value (31.4 μM) for the inhibition of GUS. Moreover, when E2 is used in the treatment of breast cancer, the daily oral dosage can reach up to 30 mg.³¹ Therefore, the inhibition of GUS may be achieved by administering E2.



This deserves further investigations, in particular consideration of potential application of irinotecan in the treatment of breast cancer.³¹ TFP acts as an anti-psychotic medicine, which is mainly used to treat anxiety or psychotic disorders.³² Based on a study conducted in rats, 87% of the administered TFP will be excreted into the gut.³³ The single oral dosage of TFP can reach 5 mg,³⁴ which may result in the TFP level to be higher than 56.9 μM in the human gut. It is possible that after the administration of TFP, GUS activity in the gut is correspondingly decreased.

Mag containing *Magnolia Officinalis* has been widely used in the treatment of multiple common diseases such as gastrointestinal disorders and anxiety in China and Japan for a very long time.³⁵ It was reported that a single dose of 5 g Sai-boku-to contained 2.1 mg Mag, and the urinary excretion was less than 10% of the total dosage.³⁶ Most of the chemical may stay in the colon with the concentration higher than 16.6 μM . One thing that needs to be noted here is Mag may also undergo extensive glucuronidation in humans.²⁶ This study did not test the inhibitory effects of Mag glucuronide towards GUS. As a good substrate for GUS, it is likely that Mag glucuronide can potentially inhibit the activity of GUS. Interestingly, after taking Mag, whether the chemical exists as a parent or a glucuronidated form, the inhibition of GUS is going to happen. As discussed previously, *Magnolia Officinalis* has been used in the treatment of gastrointestinal disorders.³⁵ Based on this study, it seems that the inhibition of GUS may partly contribute to gastrointestinal protective effects, since Mag can prevent the release of toxic parent chemicals from glucuronides.

Materials and methods

Chemicals and enzymes

Estradiol (E2, purity > 98%), testosterone (purity \geq 98%), entacapone (purity \geq 98%), and nilotinib (purity \geq 99%) were purchased from Aladdin Co., Ltd. (Shanghai, China). Trifluoperazine (TFP, purity \geq 99%), fluconazole (purity \geq 98%), and niflumic acid (purity \geq 98%) were purchased from Macklin Co., Inc. (Shanghai, China). Magnolol (MAG, purity \geq 98%) and hecogenin (purity \geq 98%) were purchased from Pufei De Biotech Co., Ltd. (Chengdu, China). 4-Nitrophenol (pNP, purity > 99%), 4-nitrophenol- β -O-glucuronide (pNPG, purity > 98%), and 3'-azido-3'-deoxythymidine (purity \geq 98%) were purchased from J&K Chemical Ltd. (Shanghai, China). Uridine diphosphate glucuronic acid (UDPGA, purity > 96%) and *E. coli* β -glucuronidase (GUS, Cat No. G8295, 25KU/2.1 mg) were purchased from Sigma-Aldrich (Shanghai, China).

Incubation conditions

Hydrolyses of pNPG by GUS were carried out at 37 °C in 200 μL mixture of 50 mM phosphate buffer (pH = 6.8). The reactions were initiated by adding 20 μL pNPG solution. Preliminary experiments demonstrated that the linear ranges of GUS and time required are 0–2 U mL^{-1} and 0–40 min, respectively. In the inhibition assays, GUS consumption in the reaction mixture and reaction time were set at 0.5 U mL^{-1} and 20 min, respectively. The reaction was stopped by adding 100 μL ice-cold

methanol. The samples were then centrifuged at 20 000g for 20 minutes to remove the protein, and 10 μL of the supernatants were analysed in the UPLC system.

Inhibition screening

Inhibitory effects towards GUS were tested for various typical substrates and inhibitors of UGTs. pNPG (200 μM) was incubated with GUS (0.1 U) in the presence of UDPGA (4 mM), E2 (100 μM), nilotinib (100 μM), TFP (100 μM), hecogenin (100 μM), entacapone (100 μM), Mag (100 μM), niflumic acid (100 μM), zidovudine (1 mM), fluconazole (1 mM) or testosterone (100 μM). Information on chemicals probing UGTs is available in the literature. Specifically, UDPGA acts as the universal substrate for all UGT isoforms.³⁷ E2, TFP, entacapone, zidovudine, and testosterone were specific substrates for UGT1A1, 1A4, 1A9, 2B7 and 2B17, respectively.^{16,23,38,39} Nilotinib, hecogenin, Mag/niflumic acid and fluconazole serve as the selective inhibitors of UGT1A1, UGT1A4, 1A9, and 2B7, respectively.^{17–19,23} The concentrations used here were set much higher (at least 5-folds) than the known affinity values to the individual UGT isoforms. All incubations were conducted at 37 °C for 20 min in triplicate.

Kinetic assays

Inhibitory constants (K_i) were determined for E2, TFP, and Mag. Various concentrations of pNPG (100, 200, 500 μM), E2 (0–200 μM), TFP (0–200 μM) and Mag (0–100 μM) were employed in the kinetic assays. Either competitive inhibition kinetic model, non-competitive inhibition model, un-competitive inhibition model, or mixed inhibition model were fitted into the kinetic data.¹⁸ The K_i values were generated from the inhibition kinetic model displaying the highest R^2 values by using Graphpad Prism 5.0. All incubations were conducted at 37 °C for 20 min in triplicate.

Docking studies

Molecular docking studies were performed to probe the interaction mode of E2, TFP, and Mag with the active sites of GUS using Surflex-Dock of the SYBYL procedure (x-1.2). The structure of GUS in a complex with inhibitor (PDB code 3LPF) was used as the receptor.¹² The B-chain of protein and hetero-atoms including the cofactors were removed from the original protein data file. The 3D structure of these three compounds were optimized by energy minimization using the default Tripos force field parameters. The Gasteiger–Hückel charges were calculated. The active pocket for inhibitor binding was generated around the crystallographic ligand in an automatic mode with the setup of float radius as zero. Compounds were docked into the active sites to observe the interaction mode.

Analysis methods

pNPG hydrolysis samples were analysed on a Waters Acquity UPLC system equipped with an ultraviolet detector. A waters C18 analytical column (50.0 mm \times 2.1 mm, I.D., 1.7 μm) was used and kept at 40 °C during the analyses. The mobile phase was composed of acetonitrile (A) and 0.1% formic acid in water



(B) at a flow rate of 0.3 mL min⁻¹, with a gradient: 0–4 min, 90% B–30% B; 4.01–8 min, 5% B; 8.01–12 min, balance to 90% B. To detect pNP and pNPG, the detector wavelength was set at 310 nm. pNP and pNPG were eluted at 3.6 and 2.4 min, respectively. Hydrolysis rates were quantified by the standard curve of pNP, which was linear at least within 0.1 to 20 μM. The intra- and inter-day RSD were both less than 2%.

Conclusions

This study identified that ligand selectivity overlaps between UGTs and GUS deserve attention in the exploration of inhibitors of these two enzymes. UGT typical ligands E2, TFP and Mag could act as competitive inhibitors of GUS *via* contacts with the residues or bound water in the enzyme active site. The inhibitory potential of the three UGT ligands could induce the inhibition of gut hydrolysis of glucuronides, further displaying protective effects on the intestinal tract.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The study was supported by National Natural Science Foundation of China (81503151), Provisional Educational & Natural Science Foundation of Anhui (2018jyssf086, 1808085QC97 and KJ2018A0355), Dalian Youth science and technology star project (2017RQ046).

References

- 1 E. C. C. Mano, A. L. Scott and K. M. Honorio, *Curr. Med. Chem.*, 2018, **25**, 3247–3255.
- 2 A. Rowland, J. O. Miners and P. I. Mackenzie, *Int. J. Biochem. Cell Biol.*, 2013, **45**, 1121–1132.
- 3 B. Sperker, J. T. Backman and H. K. Kroemer, *Clin. Pharmacokinet.*, 1997, **33**, 18–31.
- 4 P. Awolade, N. Cele, N. Kerru, L. Gummidi, E. Oluwakemi and P. Singh, *Eur. J. Med. Chem.*, 2020, **187**, 111921.
- 5 G. Ma, Y. Zhang, W. Chen, Z. Tang, X. Xin, P. Yang, X. Liu, W. Cai and M. Hu, *Mol. Pharm.*, 2017, **14**, 2952–2966.
- 6 M. Iwase, K. ichi Fujita, Y. Nishimura, N. Seba, Y. Masuo, H. Ishida, Y. Kato and Y. Kiuchi, *Cancer Chemother. Pharmacol.*, 2019, **83**, 993–998.
- 7 D. Liu, L. Zhang, L. xin Duan, J. jun Wu, M. Hu, Z. qiu Liu and C. yan Wang, *Pharmacol. Res.*, 2019, **150**, 104510.
- 8 K. M. Knights, A. Rowland and J. O. Miners, *Br. J. Clin. Pharmacol.*, 2013, **76**, 587–602.
- 9 K. Grancharov, Z. Naydenova, S. Lozeva and E. Golovinsky, *Pharmacol. Ther.*, 2001, **89**, 171–186.
- 10 J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup and S. E. Ball, *Drug Metab. Dispos.*, 2004, **32**, 1201–1208.
- 11 Z. Y. Zhong, B. Bin Sun, N. Shu, Q. S. Xie, X. G. Tang, Z. L. Ling, F. Wang, K. J. Zhao, P. Xu, M. Zhang, Y. Li, Y. Chen, L. Liu, L. Z. Xia and X. D. Liu, *Acta Pharmacol. Sin.*, 2016, **37**, 1002–1012.
- 12 B. D. Wallace, H. Wang, K. T. Lane, J. E. Scott, J. Orans, J. S. Koo, M. Venkatesh, C. Jobin, L. A. Yeh, S. Mani and M. R. Redinbo, *Science*, 2010, **330**, 831–835.
- 13 T. Kodawara, T. Higashi, Y. Negoro, Y. Kamitani, T. Igarashi, K. Watanabe, H. Tsukamoto, R. Yano, M. Masada, H. Iwasaki and T. Nakamura, *Basic Clin. Pharmacol. Toxicol.*, 2016, **118**, 333–337.
- 14 X. Lv, J. Bin Zhang, J. Hou, T. Y. Dou, G. B. Ge, W. Z. Hu and L. Yang, *Biotechnol. J.*, 2019, **14**, e1800002.
- 15 Z. M. Weng, P. Wang, G. B. Ge, Z. R. Dai, D. C. Wu, L. W. Zou, T. Y. Dou, T. Y. Zhang, L. Yang and J. Hou, *Food Chem. Toxicol.*, 2017, **109**, 975–983.
- 16 V. Uchaipichat, P. I. Mackenzie, D. J. Elliot and J. O. Miners, *Drug Metab. Dispos.*, 2006, **34**, 449–456.
- 17 J. O. Miners, K. Bowalgaha, D. J. Elliot, P. Baranczewski and K. M. Knights, *Drug Metab. Dispos.*, 2011, **39**, 644–652.
- 18 L. Zhu, G. Ge, Y. Liu, G. He, S. Liang, Z. Fang, P. Dong, Y. Cao and L. Yang, *Xenobiotica*, 2012, **42**, 1001–1008.
- 19 L. Ai, L. Zhu, L. Yang, G. Ge, Y. Cao, Y. Liu, Z. Fang and Y. Zhang, *Xenobiotica*, 2014, **44**, 320–325.
- 20 V. Uchaipichat, L. K. Winner, P. I. MacKenzie, D. J. Elliot, J. A. Williams and J. O. Miners, *Br. J. Clin. Pharmacol.*, 2006, **61**, 427–439.
- 21 R. J. Liang, Y. N. Shih, Y. L. Chen, W. Y. Liu, W. L. Yang, S. Y. Lee and H. J. Wang, *Eur. J. Pharm. Sci.*, 2020, **141**, 105093.
- 22 S. P. L. Chen, W. T. Poon, C. M. Mak, C. W. Lam, Y. L. Kwong, A. Y. W. Chan and S. Tam, *Pathology*, 2011, **43**, 273–274.
- 23 J. O. Miners, K. M. Knights, J. B. Houston and P. I. Mackenzie, *Biochem. Pharmacol.*, 2006, **71**, 1531–1539.
- 24 K. Itäaho, P. I. Mackenzie, S. I. Ikushiro, J. O. Miners and M. Finel, *Drug Metab. Dispos.*, 2008, **36**, 2307–2315.
- 25 L. Zhu, L. Xiao, Y. Xia, K. Zhou, H. Wang, M. Huang, G. Ge, Y. Wu, G. Wu and L. Yang, *Toxicol. Appl. Pharmacol.*, 2015, **283**, 109–116.
- 26 L. Zhu, G. Ge, H. Zhang, H. Liu, G. He, S. Liang, Y. Zhang, Z. Fang, P. Dong, M. Finel and L. Yang, *Drug Metab. Dispos.*, 2012, **40**, 529–538.
- 27 T. S. Rasmussen, H. Koldsø, S. Nakagawa, A. Kato, B. Schiøtt and H. H. Jensen, *Org. Biomol. Chem.*, 2011, **9**, 7807–7813.
- 28 V. N. Luine, *Horm. Behav.*, 2014, **66**, 602–618.
- 29 A. C. Johnson and R. J. Williams, *Environ. Sci. Technol.*, 2004, **38**, 3649–3658.
- 30 S. E. Pritchard, L. Marciani, K. C. Garsed, C. L. Hoad, W. Thongborisute, E. Roberts, P. A. Gowland and R. C. Spiller, *Neurogastroenterol. Motil.*, 2014, **26**, 124–130.
- 31 M. J. Ellis, F. Gao, F. Dehdashti, D. B. Jeffe, P. K. Marcom, L. A. Carey, M. N. Dickler, P. Silverman, G. F. Fleming, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder and B. A. Siegel, *J. Am. Med. Assoc.*, 2009, **302**, 774–780.
- 32 M. Tardy, M. Dold, R. R. Engel and S. Leucht, *Cochrane Database Syst. Rev.*, 2014, CD009396.
- 33 N. R. West and W. H. Vogel, *Arch. Int. Pharmacodyn. Ther.*, 1975, **215**, 318–335.



- 34 K. K. Midha, E. D. Korchinski, R. M. H. Roscoe, E. M. Hawes, J. K. Cooper and G. McKay, *J. Pharm. Sci.*, 1984, **73**, 261–263.
- 35 Y. J. Lee, Y. M. Lee, C. K. Lee, J. K. Jung, S. B. Han and J. T. Hong, *Pharmacol. Ther.*, 2011, **130**, 157–176.
- 36 M. Homma, K. Oka, H. Kobayashi, T. Nhtsuma, S. Yamamoto, H. Itoh and N. Takahashi, *J. Pharm. Pharmacol.*, 1993, **45**, 839–841.
- 37 R. Meech and P. I. Mackenzie, *Clin. Exp. Pharmacol. Physiol.*, 1997, **24**, 907–915.
- 38 P. Lautala, B. T. Ethell, J. Taskinen and B. Burchell, *Drug Metab. Dispos.*, 2000, **28**, 1385–1389.
- 39 H. Zhang, A. Basit, D. Busch, K. Yabut, D. K. Bhatt, M. Drozdik, M. Ostrowski, A. Li, C. Collins, S. Oswald and B. Prasad, *Biochem. Pharmacol.*, 2018, **156**, 32–42.

